Power Training Post-stroke
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01970592 |
|
Recruitment Status :
Completed
First Posted : October 28, 2013
Results First Posted : March 6, 2020
Last Update Posted : March 6, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Stroke | Behavioral: POWER training | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 56 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Skeletal Muscle Plasticity As An Indicator of Functional Performance Post-Stroke |
| Actual Study Start Date : | October 1, 2013 |
| Actual Primary Completion Date : | September 29, 2017 |
| Actual Study Completion Date : | May 31, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: POWER
Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
|
Behavioral: POWER training
Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
Other Name: strength training |
- Gait Speed [ Time Frame: 8 weeks ]The speed the subject chooses to walk when instructed to walk at their "comfortable speed"
- Muscle Strength [ Time Frame: 8 weeks ]The strength of the paretic lower leg muscles will be measured by asking the participants to contract their muscles as forcefully as possible. Testing will be conducted on a specialized machine called an isokinetic dynamometer. This testing is designed to assess the ability to generate muscle power. Before testing the participants will be asked to perform 5 minutes of low intensity cycling. Strength testing will include movements at the hip, knee and ankle in both legs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age 50-70,
- stroke within the past 6 to 24 months,
- residual paresis in the lower extremity (Fugl-Meyer Lower Extremity motor score <34),
- ability to walk without assistance and without an ankle foot orthotic (AFO) on the treadmill 30 seconds at speeds ranging from 0.3 - 0.8 m/s, and
- provision of informed consent.
- In addition, all subjects who meet criteria for the training portion must complete an exercise tolerance test and be cleared for participation by the study cardiologist.
Exclusion Criteria:
- Unable to ambulate at least 150 feet prior to stroke, or experienced intermittent claudication while walking;
- rating on Modified Ashworth Scale 3 at the knee or ankle;
- limited lower extremity range of motion of the knee (passive flexion Range of Motion [ROM] < 90); hip (inability to achieve neutral 0 hip extension); or ankle (inability to achieve 0 of active dorsiflexion);
- history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living (ADLs);
- History of chronic obstructive pulmonary disease (COPD) or oxygen dependence;
- Preexisting neurological disorders, dementia or previous stroke;
- History of major head trauma;
- Legal blindness or severe visual impairment;
- history of significant psychiatric illness
- Life expectancy <1 yr.,
- Severe arthritis or other problems that limit passive ROM;
- post-stroke depression (PHQ-9 10),
- History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months;
- Uncontrolled diabetes with recent diabetic coma, or frequent insulin reactions;
- Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest;
- Previous or current enrollment in a trial to enhance motor recovery;
- Presence of non-magnetic resonance (MR) compatible implants, pregnancy or severe claustrophobia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01970592
| United States, South Carolina | |
| Ralph H. Johnson VA Medical Center, Charleston, SC | |
| Charleston, South Carolina, United States, 29401-5799 | |
| Principal Investigator: | Chris M Gregory, PhD | Ralph H. Johnson VA Medical Center, Charleston, SC |
Documents provided by VA Office of Research and Development:
| Responsible Party: | VA Office of Research and Development |
| ClinicalTrials.gov Identifier: | NCT01970592 |
| Other Study ID Numbers: |
O0844-R |
| First Posted: | October 28, 2013 Key Record Dates |
| Results First Posted: | March 6, 2020 |
| Last Update Posted: | March 6, 2020 |
| Last Verified: | February 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
exercise rehabilitation walking |
|
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |

